诺瓦瓦克斯医药（NVAX）今日盘前股价大涨9.24%，主要受益于公司第一季度财报好于预期。该公司成功扭亏为盈，这主要得益于其新冠疫苗相关支出的减少。
根据公司财报，诺瓦瓦克斯第一季度收入达到6.67亿美元，远超分析师预期的3.4385亿美元。其中，6.03亿美元的收入来自两项预购协议终止后的确认。同时，公司实现净利润5.19亿美元，相比去年同期1.48亿美元的净亏损，实现了显著的转变。
展望未来，诺瓦瓦克斯上调了2025年的收入预期。公司预计2025年调整后的总收入将在9.75亿美元到10.3亿美元之间，较此前3亿美元到3.5亿美元的预期大幅提升。值得注意的是，这一预期不包括与赛诺菲合作的销售额和特许权使用费。此外，公司正在与美国监管机构就其新冠疫苗的全面批准进行谈判，一旦获得批准，将从合作伙伴赛诺菲获得1.75亿美元的里程碑付款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.